Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry

BACKGROUND: Tofacitinib is a Janus kinase inhibitor approved for the treatment of ulcerative colitis (UC). AIM: To evaluate effectiveness, safety and use of tofacitinib in daily practice. METHODS: UC patients initiating tofacitinib were prospectively enrolled in 15 hospitals in the Netherlands. Cort...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Aliment Pharmacol Ther
Autori principali: Biemans, Vince B. C., Sleutjes, Jasmijn A. M., de Vries, Annemarie C., Bodelier, Alexander G. L., Dijkstra, Gerard, Oldenburg, Bas, Löwenberg, Mark, van Bodegraven, Adriaan A., van der Meulen‐de Jong, Andrea E., de Boer, Nanne K. H., Srivastava, Nidhi, West, Rachel L., Römkens, Tessa E. H., Horjus Talabur Horje, Carmen S., Jansen, Jeroen M., van der Woude, C. Janneke, Hoekstra, Jildou, Weersma, Rinse K., van Schaik, Fiona D. M., Hoentjen, Frank, Pierik, Marieke J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Tofacitinib for Ulcerative Colitis
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7187329/
https://ncbi.nlm.nih.gov/pubmed/32237087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.15689
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi